#1 is hard, but just barely possible. #2 is unlikely--FDA doesn't schedule stuff for ANYONE's convenience. #3 is pretty much impossible, as Italy is on vacation and NICE, again, isn't scheduling actions for our convenience.
Other than that, I think #s 2&3 are pretty much non-events. Europe ex-UK and IT (&ex the already onboard DE and FR) is on the same order of size as either one of those, so the rollout can keep going without them; the $60MM is modest next to the numbers that are really interesting to people. And the money question for PV is whether adding the less-serious indication can increase the dollars of sales, not whether it can be added at all.
What (if any) sales use can be made of papers showing a MF survival benefit for Jakafi is potentially of great interest; any kind of recognition of post-facto analyses would have symbolic importance.
There's a curious tripwire hiding somewhere--some number of country approvals of Jakavi starts up a reverse royalty to Novartis, which I don't people have front-of-mind.